Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Unsolved Ecological Mystery Exposed by New Film: "Strange Nature" Now on Kickstarter
  • USA - English


News provided by

Ojala Productions

Jul 25, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Severely Deformed Frogs Outbreak
Severely Deformed Frogs Outbreak

North Hollywood, CA (PRWEB) July 25, 2013 -- Writer/Director, Jim Ojala, President of Ojala Productions is set to direct Strange Nature. The Eco-Horror feature film is based on a true unsolved ecological mystery, where thousands of hideously deformed frogs have turned up in the waters of Minnesota and beyond.

Ojala, a Duluth, Minnesota native said that he was intrigued by the Minnesota mutant frog outbreak when he saw the news story on ABC Nightline in 1996. (See Story). After watching the newscast, Jim’s first thought was what if the mutations went beyond the frogs?

Now is the time for this film to be made, it exposes a true environmental issue that has been swept under the carpet far too long.

Post this

Ojala followed the story over the next few years, as the outbreak continued to grow and in some areas. Over 70% of the frog population showed severe signs of deformity. The Minnesota Pollution Control Agency investigated the mutation problem and derived several possible theories for the cause, but no conclusion was determined. In 2001, the U.S. Government pulled research funding. The malformations have since spread to other states and even other countries-- most recently, reports from Argentina, China, and India.

The true events are the basis for "Strange Nature." “It's a horror film and a drama of sorts,” explains Ojala, “the horror as seen through the eyes of a single-mother and her 11-year old son as the drama unfolds on a small Minnesota town which struggles to survive when the deadly mutations move beyond the ponds.” Ojala passionately believes now is the time for this film to be made, “it exposes a true environmental issue that has been swept under the carpet far too long.”

After contacting several leading U.S. Ecological scientists involved in the deformed frog cases, Ojala remarks, “they truly feel let-down by the government for not taking this matter more seriously.” The scientists are in full support of "Strange Nature" to the extent that they have provided live severely deformed frogs to be featured in the film.

Ojala’s goal by making this film is two-fold: 1) to bring the story to the public attention after eighteen years and 2) to trigger further research funding which could lead to finding the cause and prevent the mutations from spreading to other species.

Once production funding is secured for "Strange Nature," Ojala will move forward with principal photography which will shoot in Minnesota. Currently, a fundraising campaign for the film is on Kickstarter until August 8th, 2013 4:49pm EDT.

About Jim Ojala and Ojala Productions

Ojala discovered his passion for directing when he joined the Duluth Public Access Station where he was given the opportunity to learn all aspects of video production. He collaborated with friends to create and direct a local cable-TV series, "My Three Scums," a notorious horror/comedy series revolving around a family of misfits, and monsters which continued for 3 years and garnered a large local following.

The success of "My Three Scums" opened the door to Ojala’s first film job with Troma Studios in New York on the film, "Citizen Toxie: The Toxic Avenger 4."

Following "Citizen Toxie," Ojala went on to work with Tim Considine of Direct Effects in the special makeup effects department. While in New York, Jim also attended the Millennium Film Program under the mentorship of experimental filmmaking pioneer, Michael Kuchar.

In 2001, Ojala made the pilgrimage to Los Angeles. One of his first jobs in LA, was working on the makeup/creature effects for "Buffy the Vampire Slayer" and "The Shield." Subsequently, he has also worked on numerous commercials, and features including "Where the Wild Things Are" and "Hellboy 2 The Golden Army." Ojala’s makeup/creature effects' skills continue to be a strong force in the independent film world providing makeup effects for the critically hailed, "Deadgirl," as well as working with Legacy Studios on the eagerly anticipated "Pacific Rim."

Ojala's directing credits range from short films, and TV Pilots, to music videos including: The viral hit fan film, "Marvel Zombies the Movie", "Harvest"- a TV pilot based on a one hour TV series, and "Deviled Egg", a music video for the popular Los Angeles Band, The Radioactive Chicken Heads to name a few.

For further information, visit Ojalafilms.com and Strangenaturemovie.com

Beth Meadows, Ojala Productions, http://www.ojalafilms.com, +1 310-890-5582, [email protected]

Modal title

About Jim Ojala and Ojala Productions
View PDF
About Jim Ojala and Ojala Productions
Ojala Productions
Ojala Productions
About Jim Ojala and Ojala Productions Ojala Productions

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.